PFG
NVO

Piershale Financial Group’s Novo Nordisk NVO Stock Holding History

Piershale Financial Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-400
Closed -$12K – 184
2015
Q4 		$12K Buy
+400
New +$11.1K 0.01% 105

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Piershale Financial Group's NVO Position: Q1 2016 in Review

Piershale Financial Group sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 400 shares — an estimated $12K sold.

Piershale Financial Group first reported a position in NVO in Q4 2015 and held it in 1 quarter. The position peaked at $12K in Q4 2015. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

  • Piershale Financial Group reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
  • Piershale Financial Group sold 400 Novo Nordisk shares in Q1 2016, an estimated $12K.
  • Piershale Financial Group first reported a position in Novo Nordisk in Q4 2015 and held it in 1 quarter.
  • Piershale Financial Group's Novo Nordisk position peaked at $12K in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Piershale Financial Group's 13F filing for Q1 2016, filed 15 Apr 2016.